Med-tech company PolarCool AB (publ.) have extended the agreement with French rugby powerhouse Racing 92 for another two years. The rugby club has successfully utilized the PolarCap® System over the past seasons to treat players with concussions.
The renewal follows a positive trend among top-tier sports clubs increasingly prioritizing concussion management and player safety. Recently, French rugby club Stade Français also extended its PolarCap® agreement for two additional years, while Finnish ice hockey team KalPa and Swedish champions Skellefteå AIK have secured long-term partnerships with PolarCool.
The extension with Racing 92’s reflects the club’s dedication to enhancing player safety. The basis for the extension is a combination of the compelling results from the published 5-year clinical study bolstered by the clubs positive first-hand experiences with PolarCap®.
PolarCool CEO Erik Andersson comments:
-Having a leading club like Racing 92 extend its agreement with us is strategically significant. It confirms customer satisfaction and demonstrates the clinical efficacy of PolarCap® reinforcing its place as a treatment in the international rugby market. Additionally, we see a consistently high proportion of clubs choosing to renew their agreements with us.
PolarCool now has a strong foothold in World rugby with customers providing the treatment across nine countries. The agreement with Racing 92 is strategically important, even if the financial significance of individual agreements is limited.
For more information
Erik Andersson – CEO PolarCool AB (publ.)
+46 – 738 60 57 00
E-mail: erik.andersson@polarcool.se
About PolarCool AB (publ.)
PolarCool AB (publ.) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ.) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.